Introducing PeptAI: Autonomous Agents for Peptide Drug Discovery
Join us next Tuesday for a livestream unveiling PeptAI, a fleet of autonomous agents for peptide drug discovery.
More about PeptAI
Peptide drug discovery is bottlenecked by coordination cost between discovery, synthesis, and wet-lab validation. PeptAI removes those handoffs:
Each agent runs a 9-gate pipeline 24/7 against a single receptor
Every gate decision publishes openly on Molecule Labs
Agents pay for their own wet-lab synthesis at Adaptyv Bio via x402
Two agents are running with candidates advancing, and a third has a lead ready for wet lab.
If successful, PeptAI validates a new model for autonomous biotech R&D: pre-IND-ready peptide assets produced end-to-end by agents, with every decision auditable on-chain.
The opportunity
Peptide therapeutics: $49.5B market by 2030 (10.2% CAGR)
80+ FDA-approved peptide drugs, 150+ in active trials
AI-driven drug discovery: $1.3B by 2030 (30%+ CAGR)
PEPTAI holders co-own the proprietary wet-lab data generated across every candidate and receptor program, data biotech, pharma, and AI drug discovery companies actively buy
Governance over target and receptor decisions, share in revenues from commercialized discoveries, early exposure to a pipeline heading to pre-IND
Roadmap
Live now:
Agent-01 (GLP-1R): 35 candidates advancing
Agent-02 (KISS1R): 2 of 10 advanced to G9
Agent-03 (OX2R): lead candidate ready for wet lab
Next:
Q2 2026
First on-chain wet-lab attestation via @Molecule_sci Labs
Q3 2026
Autonomous iteration cycle proven, GLP-1R Gen 1 library, design-vs-nature bioRxiv preprint
Q4 2026
Pipeline scales beyond GPCRs
Q1 2027
Lead optimization at scale, pre-IND scoping
Q2 2027
First in vivo studies, multi-target portfolio in parallel
Funding
Initial Raise: $50K
Starting FDV: $1M
Initial Project Funding: $25K, with further unlocks tied to scientific milestones